Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...